JP2020536107A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536107A5 JP2020536107A5 JP2020519400A JP2020519400A JP2020536107A5 JP 2020536107 A5 JP2020536107 A5 JP 2020536107A5 JP 2020519400 A JP2020519400 A JP 2020519400A JP 2020519400 A JP2020519400 A JP 2020519400A JP 2020536107 A5 JP2020536107 A5 JP 2020536107A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine composition
- composition according
- dengue
- administered
- vaccination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762568525P | 2017-10-05 | 2017-10-05 | |
| US62/568,525 | 2017-10-05 | ||
| PCT/IB2018/001219 WO2019069130A1 (en) | 2017-10-05 | 2018-10-05 | COMPOSITIONS FOR RECALL VACCINATION AGAINST DENGUE |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020536107A JP2020536107A (ja) | 2020-12-10 |
| JP2020536107A5 true JP2020536107A5 (https=) | 2021-11-11 |
| JP7313345B2 JP7313345B2 (ja) | 2023-07-24 |
Family
ID=64184125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020519400A Active JP7313345B2 (ja) | 2017-10-05 | 2018-10-05 | デング熱に対するブースターワクチン接種のための組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11690903B2 (https=) |
| EP (1) | EP3691681A1 (https=) |
| JP (1) | JP7313345B2 (https=) |
| AU (1) | AU2018346724B2 (https=) |
| SG (1) | SG11202002933TA (https=) |
| WO (1) | WO2019069130A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019069130A1 (en) * | 2017-10-05 | 2019-04-11 | Sanofi Pasteur | COMPOSITIONS FOR RECALL VACCINATION AGAINST DENGUE |
| WO2022123470A1 (en) * | 2020-12-10 | 2022-06-16 | Reagene Biosciences Pvt. Ltd. | Saliva based diagnostic assays for detection of sarscov2 receptor binding domain (rbd) neutralizing antibodies |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996040933A1 (en) | 1995-06-07 | 1996-12-19 | The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services | Infectious dengue 2 virus pdk-53 as quadravalent vaccine |
| US6962708B1 (en) | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
| EP0977587B1 (en) | 1997-02-28 | 2005-06-15 | Acambis Inc. | Chimeric flavivirus vaccines |
| US7227011B2 (en) | 1998-06-04 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
| WO2000057909A2 (en) | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research | Attenuated dengue-2 virus vaccine |
| US6537557B1 (en) | 1999-03-26 | 2003-03-25 | The United States Of America As Represented By The Secretary Of The Army | Attenuated dengue-4 virus vaccine |
| CA2368790A1 (en) | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research | Attenuated dengue-3 virus vaccine |
| JP2002540169A (ja) | 1999-03-26 | 2002-11-26 | ウォルター リード アーミー インスティテュート オブ リサーチ | 弱毒化デング熱１型ウイルスワクチン |
| AU1813901A (en) | 1999-12-01 | 2001-06-12 | Oravax, Inc | Chimeric flavivirus vaccines |
| ATE526411T1 (de) | 2000-02-16 | 2011-10-15 | Us Gov Health & Human Serv | Avirulente, immunogene flavivirus-chimäre |
| ATE412738T1 (de) | 2000-05-30 | 2008-11-15 | Univ Mahidol | Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen |
| AT410634B (de) | 2001-02-21 | 2003-06-25 | Franz X Dr Heinz | Attenuierte lebendimpfstoffe |
| CA2966716C (en) | 2001-05-22 | 2019-11-26 | The Government Of The United States Of America, As Represented By The Cretary, Department Of Health And Human Services | Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses |
| CN1551782A (zh) | 2001-06-01 | 2004-12-01 | ��������ķ������ | 嵌合黄病毒载体 |
| KR101074175B1 (ko) | 2002-01-15 | 2011-10-14 | 사노피 파스테르 바이오로직스 씨오 | 플라비바이러스 백신 |
| US20050002968A1 (en) | 2002-01-15 | 2005-01-06 | Monath Thomas P. | Flavivirus vaccines |
| US20040259224A1 (en) | 2002-05-31 | 2004-12-23 | Farshad Guirakhoo | Tetravalent Dengue vaccines |
| CN101238144B (zh) | 2005-06-17 | 2012-09-05 | 赛诺菲巴斯德有限公司 | 登革血清型1减毒株 |
| CA2611954C (en) | 2005-06-17 | 2014-01-28 | Sanofi Pasteur | Dengue serotype 2 attenuated strain |
| JP5227172B2 (ja) | 2005-08-10 | 2013-07-03 | サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー | デングウイルス感染に対するワクチン接種 |
| KR101357685B1 (ko) | 2005-11-21 | 2014-02-06 | 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 | 재조합 바이러스용 안정화 제형 |
| CU23586A1 (es) | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus |
| US7968102B2 (en) | 2006-01-13 | 2011-06-28 | Sanofi Pasteur S.A. | Dengue chimeric viruses |
| FR2903605A1 (fr) | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| FR2906724B1 (fr) | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
| FR2909286B1 (fr) | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
| EP2117589A4 (en) | 2007-01-31 | 2010-07-21 | Sanofi Pasteur Biologics Co | FLAVIVIRUS VACCINE VECTOR AGAINST INFLUENZA VIRUS |
| AU2009241354B2 (en) | 2008-04-30 | 2014-06-12 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Chimeric West Nile/Dengue viruses |
| EP2143440A1 (fr) | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
| US8968996B2 (en) | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
| KR20140015127A (ko) | 2009-07-29 | 2014-02-06 | 베른드 헬무트 아담 렘 | 폴리머 입자 및 이의 용도 |
| EP2353609A1 (en) | 2010-02-04 | 2011-08-10 | Sanofi Pasteur | Immunization compositions and methods |
| GB201007531D0 (en) | 2010-05-05 | 2010-06-23 | Imp Innovations Ltd | Composition |
| WO2011146933A2 (en) | 2010-05-21 | 2011-11-24 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Universal dengue virus sequences and methods of use |
| WO2012051491A1 (en) | 2010-10-14 | 2012-04-19 | The United States Of America, As Represented By The Secretary National Institutes Of Health | Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting |
| AU2013295016A1 (en) | 2012-07-24 | 2015-01-29 | Sanofi Pasteur | Vaccine compositions for prevention against dengue virus infection |
| SG10201912291YA (en) | 2012-07-24 | 2020-02-27 | Sanofi Pasteur | Vaccine compositions |
| US10518409B2 (en) * | 2014-09-02 | 2019-12-31 | Mark Oleynik | Robotic manipulation methods and systems for executing a domain-specific application in an instrumented environment with electronic minimanipulation libraries |
| TWI852899B (zh) | 2014-09-02 | 2024-08-21 | 法商賽諾菲巴斯德公司 | 疫苗組合物 |
| WO2017005654A1 (en) | 2015-07-03 | 2017-01-12 | Sanofi Pasteur | Concomitant dengue, diphtheria, tetanus, whooping cough (pertussis), polio, and haemophilus influenzae type b vaccination. |
| EP3316905A1 (en) | 2015-07-03 | 2018-05-09 | Sanofi Pasteur | Concomitant dengue and yellow fever vaccination |
| WO2019069130A1 (en) * | 2017-10-05 | 2019-04-11 | Sanofi Pasteur | COMPOSITIONS FOR RECALL VACCINATION AGAINST DENGUE |
-
2018
- 2018-10-05 WO PCT/IB2018/001219 patent/WO2019069130A1/en not_active Ceased
- 2018-10-05 SG SG11202002933TA patent/SG11202002933TA/en unknown
- 2018-10-05 JP JP2020519400A patent/JP7313345B2/ja active Active
- 2018-10-05 EP EP18799824.0A patent/EP3691681A1/en active Pending
- 2018-10-05 AU AU2018346724A patent/AU2018346724B2/en active Active
- 2018-10-05 US US16/652,902 patent/US11690903B2/en active Active
-
2023
- 2023-06-02 US US18/328,403 patent/US20230338504A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement | |
| Cai et al. | A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses | |
| Minor | Live attenuated vaccines: Historical successes and current challenges | |
| Foo et al. | Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide | |
| Ikegami et al. | Rift valley fever vaccines | |
| Simmons et al. | Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy | |
| Wang et al. | Inactivated rotavirus vaccine induces protective immunity in gnotobiotic piglets | |
| Zhou et al. | Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys | |
| JP2019151636A5 (https=) | ||
| Xiang et al. | Protection of non-human primates against rabies with an adenovirus recombinant vaccine | |
| Bröker et al. | After a tick bite in a tick-borne encephalitis virus endemic area: current positions about post-exposure treatment | |
| Baehner et al. | Vaccines against norovirus: state of the art trials in children and adults | |
| Terhuja et al. | Comparative efficacy of virus like particle (VLP) vaccine of foot-and-mouth-disease virus (FMDV) type O adjuvanted with poly I: C or CpG in guinea pigs | |
| JP2017526689A5 (https=) | ||
| Martinelle et al. | Assessment of cross-protection induced by a bluetongue virus (BTV) serotype 8 vaccine towards other BTV serotypes in experimental conditions | |
| Calvo-Pinilla et al. | Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48 h before, or 48 h after challenge | |
| CN113329767B (zh) | 肠道病毒对vero细胞的适应及其疫苗制剂 | |
| Abente et al. | Alphavirus-vectored hemagglutinin subunit vaccine provides partial protection against heterologous challenge in pigs | |
| Moreno et al. | Recombinant Rift Valley fever viruses encoding bluetongue virus (BTV) antigens: Immunity and efficacy studies upon a BTV-4 challenge | |
| Phillpotts et al. | Monoclonal antibody protects mice against infection and disease when given either before or up to 24 h after airborne challenge with virulent Venezuelan equine encephalitis virus | |
| Calvo-Pinilla et al. | The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host | |
| JP2020536107A5 (https=) | ||
| Zhang et al. | Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for Coxsackievirus A16 and Enterovirus 71 | |
| Zhou et al. | Recombinant adenovirus expressing type Asia1 foot-and-mouth disease virus capsid proteins induces protective immunity against homologous virus challenge in mice | |
| Van Rijn et al. | Bluetongue Disabled Infectious Single Animal (DISA) vaccine: Studies on the optimal route and dose in sheep |